0401.HK stock down 29.23% to HK$0.09 on 06 Feb 2026 HKSE: check liquidity and valuation

We saw 0401.HK stock slip 29.23% intraday to HK$0.09 on 06 Feb 2026 on the HKSE, making it one of Hong Kong’s top losers in the session. The fall follows heavy trading with volume at 1,903,600.00 shares versus an average of 255,215.00. Short-term momentum turned negative and the drop widened the gap below the 50-day average of HK$0.11. Traders should weigh liquidity, negative EPS and sector context before acting.

Intraday price action on 0401.HK stock

Wanjia Group Holdings Limited (0401.HK) opened at HK$0.11 and hit a day low of HK$0.09. The stock fell HK$0.04 from the previous close of HK$0.13. The one-day percent move of -29.23% outpaced the healthcare sector’s intraday move of -1.53%, signalling a company-specific driver rather than broad sector weakness.

Fundamentals and valuation for 0401.HK stock

Wanjia Group shows trailing EPS -0.02 and PE -6.25, reflecting a loss-making profile. Market cap is HK$70,027,767.00 with 560,222,136.00 shares outstanding. Price to sales is 0.23 and price to book is 0.85, below many healthcare peers. Compare to Hong Kong healthcare average PE 29.06, where 0401.HK’s negative PE flags profitability risk despite low sales multiples.

Technicals, volume and trading signals for 0401.HK stock

Technical indicators show RSI 41.69 and ADX 32.25, suggesting a strong short-term trend to the downside. Bollinger middle band sits at HK$0.11 with lower band HK$0.09, matching today’s low. On-balance volume is 3,922,493.00, but average volume is 255,215.00, so the intraday volume spike is meaningful and may confirm distribution.

Meyka AI grade and 0401.HK stock forecast

Meyka AI rates 0401.HK with a score out of 100: 64.66 / 100 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price near HK$0.15. Current price is HK$0.09, implying an upside of 58.96% to the yearly forecast. Forecasts are model-based projections and not guarantees.

Risks and catalysts for 0401.HK stock

Key risks include continued negative EPS, weak interest coverage -3.86, and volatile liquidity at low absolute price levels. Catalysts that could stabilise shares include better-than-expected earnings, contract gains in pharmaceutical distribution, or clearer guidance on dialysis service margins. Watch receivables and inventory turnover; days sales outstanding sits at 35.21 and inventory days at 29.05.

Price targets, strategy and 0401.HK stock outlook

Analyst-style price targets for 0401.HK: conservative HK$0.12, base HK$0.15, bull HK$0.23. Short-term traders should prioritise stop-loss rules and monitor average volume of 255,215.00 as liquidity can evaporate. Long-term holders should track margin improvement and filings on revenue mix. For real-time updates consult the company website and our Meyka page.

Final Thoughts

0401.HK stock registered a sharp intraday fall to HK$0.09 on 06 Feb 2026, driven by heavy trading and weak near-term momentum. Fundamentals show negative EPS -0.02 and negative profitability metrics, but attractive multiples such as price to sales 0.23 and price to book 0.85. Meyka AI’s forecast model projects a yearly price of HK$0.15, which implies a 58.96% upside from the current HK$0.09. That projection assumes margin recovery and steady distribution revenue growth. Given the company’s small market cap of HK$70,027,767.00 and fragile interest coverage, the risk profile remains elevated. We view 0401.HK stock as a speculative holding for risk-tolerant investors, and recommend monitoring volume, upcoming earnings, and any company filings before reallocating capital. For live disclosures see Wanjia Group website and our Meyka stock page. Meyka AI provides AI-powered market analysis but forecasts are model-based and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.